InsidersTradesSigma
Follow the Champions Oncology, INC. stock price and the full management transaction log of the company, a publicly traded company based in United States. Shares are listed on the US market, under the oversight of SEC (Form 4). Operating in the Healthcare & Pharma sector, Champions Oncology, INC. has logged 36 reports. Market capitalisation: €84.7m. The latest transaction was filed on 6 November 2025 (Levée d'options). Among the most active insiders: Mendelson Daniel Newman. All data is openly available.
36
Insider Decl.
n/a
Thresholds
€459,875
26 ops.
Buy Volume
n/a
n/a
Sell Volume
28Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 25,460 of 29,063 companies
24.4
score / 100
Value23
Quality26
FCF yld-7.1%
Earn yld-1.7%
EV/EBITDA·
ROE-30%
Gross mgn48%
Net mgn-2.0%
Debt/EBITDA13.0x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 6 November 2025
Declarations36 total
94,405 shares@ US$2.1027.4% of flowCommon StockSEC:0001628280-25-049954:0
4,150 shares0Common StockSEC:0001628280-25-016197:0
88,470 shares@ US$2.1037.7% of flowCommon StockSEC:0001628280-24-044663:0
1,000 shares@ US$6.501.4% of flowCommon StockSEC:0001628280-24-001334:0
Canonical exit: 11 Apr 2024 (T+90)
2,000 shares@ US$6.272.8% of flowCommon StockSEC:0001628280-24-001231:0
Canonical exit: 10 Apr 2024 (T+90)
2,944 shares@ US$6.314.1% of flowCommon StockSEC:0001628280-24-001118:0
Canonical exit: 9 Apr 2024 (T+90)
3,000 shares@ US$6.254.1% of flowCommon StockSEC:0001628280-24-001002:0
Canonical exit: 8 Apr 2024 (T+90)
1,000 shares@ US$6.151.4% of flowCommon StockSEC:0001628280-24-000896:0
Canonical exit: 7 Apr 2024 (T+90)
2,000 shares@ US$6.092.7% of flowCommon StockSEC:0001628280-24-000825:0
Canonical exit: 4 Apr 2024 (T+90)
3,000 shares@ US$6.124.1% of flowCommon StockSEC:0001628280-24-000820:0
Canonical exit: 3 Apr 2024 (T+90)
114,552 shares@ US$2.1050.2% of flowCommon StockSEC:0001628280-24-000639:0
500 shares@ US$5.830.6% of flowCommon StockSEC:0001628280-24-000388:0
Canonical exit: 2 Apr 2024 (T+90)
2,500 shares@ US$4.922.7% of flowCommon StockSEC:0001628280-23-042662:0
Canonical exit: 20 Mar 2024 (T+90)
2,100 shares@ US$4.822.2% of flowCommon StockSEC:0001628280-23-042467:0
Canonical exit: 19 Mar 2024 (T+90)
5,000 shares@ US$4.755.3% of flowCommon StockSEC:0001628280-23-042096:0
Canonical exit: 18 Mar 2024 (T+90)
5,000 shares@ US$6.227.1% of flowCommon StockSEC:0001628280-23-034407:0
Canonical exit: 27 Dec 2023 (T+90)
4,000 shares@ US$6.165.7% of flowCommon StockSEC:0001628280-23-034409:0
Canonical exit: 28 Dec 2023 (T+90)
1,500 shares@ US$5.952.1% of flowCommon StockSEC:0001628280-23-034405:0
Canonical exit: 26 Dec 2023 (T+90)
5,000 shares@ US$6.407.3% of flowCommon StockSEC:0001628280-23-034348:0
Canonical exit: 9 Jan 2024 (T+90)
1,100 shares@ US$6.411.6% of flowCommon StockSEC:0001628280-23-034231:0
Canonical exit: 8 Jan 2024 (T+90)
1,530 shares@ US$6.482.3% of flowCommon StockSEC:0001628280-23-034119:0
Canonical exit: 4 Jan 2024 (T+90)
2,000 shares@ US$6.473.0% of flowCommon StockSEC:0001628280-23-034004:0
Canonical exit: 3 Jan 2024 (T+90)
5,000 shares@ US$6.407.4% of flowCommon StockSEC:0001628280-23-033842:0
Canonical exit: 2 Jan 2024 (T+90)
2,500 shares@ US$6.303.6% of flowCommon StockSEC:0001628280-23-033843:0
Canonical exit: 1 Jan 2024 (T+90)
5,000 shares@ US$5.6513.0% of flowCommon StockSEC:0001628280-23-033077:0
Canonical exit: 25 Dec 2023 (T+90)
25 of 36 declarations
关于 Champions Oncology, INC.
Champions Oncology, Inc.（股票代码：CSBR）是一家在美国纳斯达克市场上市的美国公司，专注于为生物制药客户提供转化肿瘤学和研究服务。公司总部位于新泽西州哈肯萨克，围绕帮助制药和生物技术合作伙伴在药物开发周期的早期更好地了解肿瘤生物学、治疗反应和耐药机制，建立了利基市场地位。其历史可追溯到 1990 年代后期，随着时间的推移，业务已从肿瘤模型平台发展成为更广泛的肿瘤解决方案提供商，结合了临床前研究、临床支持和数据货币化。 公司的核心业务围绕患者来源异种移植（PDX）模型展开，其中将人类肿瘤植入免疫缺陷小鼠体内，以更好地模拟癌症在患者体内的行为。Champions Oncology 运营着业内最大、注释最完善的 PDX 模型库之一，并提供整合的体内和体外工作流程。其主要业务线包括药物发现和优化支持、转化药理学研究、临床生物分析服务，以及基于多组学和功能注释肿瘤数据集的新兴数据许可业务。 从竞争角度来看，Champions 在肿瘤研究服务提供商中占据着专业但重要的地位。其差异化之处不在于规模，而在于科学深度、临床相关性以及在开发早期生成可操作数据的能力。这使其对寻求降低转化风险并做出更好管线决策的生物制药客户具有吸引力。公司还在美国设有研究机构，并在以色列设有生物信息学/计算生物学部门，从而增强了其数据导向的能力。 近期里程碑事件意义重大。2025 年，Champions Oncology 报告了创纪录的收入、提高的盈利能力，并明确推动高利润数据和平台服务的增长。公司还推出了放射性药物服务平台，扩展了其同位素相关能力，并继续在 AACR 2026 等主要行业会议上展示新的科学数据。对于投资者而言，CSBR 是一家在纳斯达克上市的小盘医疗保健公司，受生物技术支出周期的影响，但在精准肿瘤学和转化研究领域拥有差异化平台。
